---
figid: PMC8623313__ijms-22-12217-g001
figtitle: Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus
  on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension
organisms:
- Homo sapiens
- Rattus norvegicus
- Euonymus japonicus
pmcid: PMC8623313
filename: ijms-22-12217-g001.jpg
figlink: /pmc/articles/PMC8623313/figure/ijms-22-12217-f001/
number: F1
caption: Targets of sorafenib, lenvatinib and cabozantinib. The intracellular signaling
  pathway MAPK and the PI3K/AKT/mTOR pathway are involved in the development of TC.
  VEGFR (vascular endothelial growth factor receptor), PDGFR (platelet-derived growth
  factor receptor), FGFR (fibroblast growth factor receptor), RET (rearranged during
  transfection), c-KIT (stem cell factor receptor), RAS (rat sarcoma protein), MET
  (Hepatocyte growth factor receptor), RAF (rapidly accelerated fibrosarcoma kinase),
  MEK (mitogen-activated protein kinase kinase), MAPK (mitogen-activated protein kinase),
  PI3K (phosphoinositide 3-kinase), AKT (protein kinase B), mTOR (mammalian target
  of rapamycin) [,,]. Adapted from [,,]. The figure was drawn using Biorender.com
  (accessed on 21 October 2021).
papertitle: Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus
  on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension.
reftext: Anne Christine Kaae, et al. Int J Mol Sci. 2021 Nov;22(22):12217.
year: '2021'
doi: 10.3390/ijms222212217
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI
keywords: thyroid cancer | multikinase inhibitors | sorafenib | cabozantinib | lenvatinib
  | adverse effects | hypertension
automl_pathway: 0.9509313
figid_alias: PMC8623313__F1
figtype: Figure
organisms_ner:
- Homo sapiens
- Rattus norvegicus
redirect_from: /figures/PMC8623313__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8623313__ijms-22-12217-g001.html
  '@type': Dataset
  description: Targets of sorafenib, lenvatinib and cabozantinib. The intracellular
    signaling pathway MAPK and the PI3K/AKT/mTOR pathway are involved in the development
    of TC. VEGFR (vascular endothelial growth factor receptor), PDGFR (platelet-derived
    growth factor receptor), FGFR (fibroblast growth factor receptor), RET (rearranged
    during transfection), c-KIT (stem cell factor receptor), RAS (rat sarcoma protein),
    MET (Hepatocyte growth factor receptor), RAF (rapidly accelerated fibrosarcoma
    kinase), MEK (mitogen-activated protein kinase kinase), MAPK (mitogen-activated
    protein kinase), PI3K (phosphoinositide 3-kinase), AKT (protein kinase B), mTOR
    (mammalian target of rapamycin) [,,]. Adapted from [,,]. The figure was drawn
    using Biorender.com (accessed on 21 October 2021).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MET
  - KDR
  - FLT1
  - FLT4
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - RET
  - MTOR
  - PDGFRB
  - PDGFRA
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - ECT
  - KIT
  - Pik3cg
  - Akt1
  - Ret
  - Mtor
  - Kit
---
